Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
2012/05/02 by Michelle Petri, Ana‐Maria Orbai, Graciela S. Alarcón +60 · 42 citations
Medicine · #Systemic Lupus Erythematosus Research #Rheumatoid Arthritis Research and Therapies #Cytomegalovirus and herpesvirus research
paper · doi:10.1002/art.34473
Abstract
OBJECTIVE: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE. METHODS: The classification criteria were derived from a set of 702 expert-rated patient scenarios. Recursive partitioning was used to derive an initial rule that was simplified and refined based on SLICC physician consensus. The SLICC group validated the classification criteria in a new validation sample of 690 new expert-rated patient scenarios. RESULTS: Seventeen criteria were identified. In the derivation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (49 versus 70; P = 0.0082) and had greater sensitivity (94% versus 86%; P < 0.0001) and equal specificity (92% versus 93%; P = 0.39). In the validation set, the SLICC classification criteria resulted in fewer misclassifications compared with the current ACR classification criteria (62 versus 74; P = 0.24) and had greater sensitivity (97% versus 83%; P < 0.0001) but lower specificity (84% versus 96%; P < 0.0001). CONCLUSION: The new SLICC classification criteria performed well in a large set of patient scenarios rated by experts. According to the SLICC rule for the classification of SLE, the patient must satisfy at least 4 criteria, including at least one clinical criterion and one immunologic criterion OR the patient must have biopsy-proven lupus nephritis in the presence of antinuclear antibodies or anti-double-stranded DNA antibodies.
Citations
Cited by
- Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
- Genetic risk factors and clinical manifestations of systemic lupus erythematosus: Large‐scale analysis of genetic predisposition and disease subtypes
- A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
- Temporal trends in lupus pregnancy over four decades in a referral centre: pregnancy planning and hydroxychloroquine use are associated with improved outcomes
- Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden
- Agreement between parent- and self-report of executive functioning in childhood-onset systemic lupus erythematosus: implications for clinical practice
- Applying Genetic Risk Score to Improve Risk Assessment of New‐Onset Lupus Nephritis in Systemic Lupus Erythematosus: A Large‐Scale Prospective Cohort Study
- Toll-like receptor expression and functional behavior in platelets from patients with systemic lupus erythematosus
- SELECTION OF ANTI-NUCLEAR ANTIGEN (ANA) REACTIVE B CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS
- Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
- Xist ribonucleoproteins promote female sex-biased autoimmunity
- Placental malperfusion and angiogenesis‐related proteins are associated with small‐for‐gestational‐age in systemic lupus erythematosus
- Achievement of lupus low disease activity state (LLDAS) in a New Zealand cohort: a prospective study of ethnic differences in outcomes
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
- Neutrophil FcγRI expression as a determinant of oxidative responses in human blood
- Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients With Systemic Lupus Erythematosus
- Antinuclear antibodies in healthy people and non-rheumatic diseases – diagnostic and clinical implications
- Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. [europepmc]
- Cutaneous lupus erythematosus: diagnosis and treatment. [europepmc]
- The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. [europepmc]
- Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. [europepmc]
- End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. [europepmc]
- Haematological manifestations of lupus. [europepmc]
- mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. [europepmc]
- Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. [europepmc]
- Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. [europepmc]
- Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. [europepmc]
- Alterations of the gut microbiome in Chinese patients with systemic lupus erythematosus. [europepmc]
- Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity. [europepmc]
- Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. [europepmc]
- Systemic lupus erythematosus: Diagnosis and clinical management. [europepmc]
- Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. [europepmc]
- Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. [europepmc]
- The Role of Epigenetics in Autoimmune/Inflammatory Disease. [europepmc]
- 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. [europepmc]
- Autoantibodies in SLE: Specificities, Isotypes and Receptors. [europepmc]
- Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. [europepmc]
- Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. [europepmc]
- New insights into the role of antinuclear antibodies in systemic lupus erythematosus. [europepmc]
- Lupus nephritis: clinical presentations and outcomes in the 21st century. [europepmc]
- Global epidemiology of systemic lupus erythematosus. [europepmc]
- Xist ribonucleoproteins promote female sex-biased autoimmunity. [europepmc]
Related